Clinical Trial Available for Untreated DLBCL

Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

Update: this study is closed to enrollment. 

Although many patients with diffuse large B cell lymphoma are cured with initial treatment, some patients do not respond well to therapy, or they relapse after an initial response. Certain factors have been shown to predict the probability of responding well, but they are not able to define whether an individual patient will respond well to treatment.

In this study, we are examining the ability of FDG-PET scanning early on in treatment to predict the ultimate outcome of that treatment in an individual patient. We hope to use the information gained in this study to individualize treatment in the future.

Key eligibility:

  • Diagnosis of CD20+ diffuse large B-cell lymphoma (DLBCL) of any stage, including subtypes:
  • Mediastinal large B-cell
  • Centroblastic
  • Immunoblastic
  • T-cell rich B-cellmed
  • Anaplastic B-cell lymphoma
  • No prior anti-lymphoma therapy

Click here for a more detailed description of this study or contact June Greenberg, RN at (212) 746-2651 or

Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

Update: this study is closed to enrollment. 

Previous expericence with antibody therapy in both non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) suggests the need for further exploration of new antibody treatments for these diseases.

This is a Phase I, open-label study being conducted in patients with recurrent non-Hodgkin’s lymphoma or chronic lymphocytic leukemia who have progressed after at least one prior standard treatment.

Click here to for the clinical and research profile of John Leonard, MD, the physician leading the study.

Treatment Research Study Available for Untreated Hodgkin Lymphoma

Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma

Update: this study is closed to enrollment. 

Patients in this study will be treated with ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) on Days 1 and 15 of each cycle according to standard treatment guidelines.  The purpose of this study is to determine the progression-free survival at 36 months for patients with Hodgkin lymphoma who achieve a response after one cycle of ABVD chemotherapy.

Click here for more information on this study for people with untreated Hodgkin lymphoma or call June Greenberg, RN at (212) 746-2651.

Click here for the clinical and research profile of Rebecca Elstrom, MD, the physician leading the study at Weill Cornell Medical Center.

%d bloggers like this: